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Abstract
Objective: Fluorophore-labeled contrast imaging agents are moving toward clinical use for a
number of applications. The near-infrared dye IRDye 800CW is frequently used in its N-
hydroxysuccinamide (NHS) ester form for labeling these agents. Following conjugation or
breakdown of a labeled ligand, excess NHS ester is converted to the carboxylate form. To
prepare for clinical use as a near-infrared fluorophore, a toxicity study was conducted on IRDye
800CW carboxylate.
Methods: Male and female Sprague–Dawley rats were given a single intravenous or intradermal
administration of IRDye 800CW carboxylate; Indocyanine Green was used as a comparative
control. Animals were injected with varying doses of the test and control articles and observed
for up to 14 days. Clinical chemistry, hematological, and pharmacokinetic analyses were
performed on subgroups of animals. Organs were analyzed for content of the test article.
Tissues were analyzed microscopically for pathological changes.
Results: Based on hematologic, clinical chemistry, and histopathologic evaluation, single
administration of IRDye 800CW carboxylate intravenously at dose levels of 1, 5, and 20 mg/kg or
20 mg/kg intradermally produced no pathological evidence of toxicity.
Conclusion: A dose of 20 mg/kg was identified as the no observed adverse effect level following
IV or ID routes of administration of IRDye 800CW.
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Introduction
W
ith recent advances in optical imaging technology and
instrumentation, targeted fluorophore-labeled contrast
agents are moving toward translation to human clinical
diagnostic use. The primary applications for clinical optical
imaging are envisioned to be aids in real-time intraoperative
surgical resection of tumors and nodal metastases, endoscopy,
and lymphovascular imaging. Near-infrared (NIR) fluorescent
dyes (Ex9750 with red-shifted emission) are the preferred
signal-generating molecules for labeling targeted ligands
owing to the significant tissue penetration of excitation light
and red-shifted emission light and the lack of autofluorescence
owing to endogenous fluorochromes [1, 2].
Indocyanine green (ICG) has been used for decades as an
angiographic contrast agent and has been recently translated to
the clinic for noninvasive lymph mapping [3–6]. More
recently, the demonstrated use of ICG at microdose admin-
istrations [7, 8] bodes well for NIR fluorescence imaging as a
clinically viable molecular imaging modality. Unfortunately,
the clinically approved form of ICG does not have a reactive
functional group and cannot be used to label targeting agents.
There has been considerable recent effort to develop
general-purpose NIR fluorophores that can be conjugated to
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agents. IRDye 800CW is a NIR dye that can be functionalized
with either an NHS or maleimide reactive group, allowing it to
be attached to a number of biomolecules. Tanaka et al. [9]
reported the successful use of IRDye 800CW-labeled human
serum albumin for sentinel lymph node mapping and surgical
resection of spontaneous metastatic melanomas in Sinclair
minipigs. Inanother study, Trastuzumab was dual-labeledwith
111In and IRDye 800CW to detect Her2-expressing xenografts
in nude mice [10]. The authors concluded that the dual-labeled
agent may be an effective agent for tracking Her2 over-
expression in breast cancer patients. Houston et al. [11]
compared gamma scintigraphy and NIR fluorescence imaging
using a dual-labeled cyclic RGD motif to show that on a 1:1
labeling basis, the NIR fluorescence from IRDye 800CW
provided greater signal to noise than the radiotracer
111In, even
thoughcameraintegrationtimeswerehundredsofmilliseconds
rather than minutes long.
Before any agent can be used in human clinical inves-
tigations, it must undergo rigorous toxicity testing, the first
stage ofwhichmustbeconducted inanimals.Inanticipationof
its use in humans, we conducted a preliminary study of the
toxicity of IRDye 800CW carboxylate since this is the relevant
form of the dye remaining after conjugation or breakdown of a
labeled ligand. The study was conducted in male and female
Sprague–Dawley rats using both IV and ID routes of
administration of several dye concentrations. The highest
concentration of dye administered was anticipated to be toxic.
For comparison, a control set of rats were treated with ICG. To
ourknowledge,thisisthefirsttoxicityreportofaNIRdyewith
the functional potential for labeling targeted ligands. Our study
opens new opportunities for safety and toxicity testing of
conjugates employing IRDye 800CW.
Materials and Methods
Near-Infrared Dyes
IRDye 800CW carboxylate was obtained from LI-COR Biosciences
(Lincoln, NE). The dye structure and purity was confirmed by HPLC,
UV/visible spectroscopy, mass spectroscopy, and NMR on multiple
dye lots. Purity was 998% by HPLC.
For mass spectroscopy, a 2 μM IRDye 800CW carboxylate
solution in 0.1% formic acid was directly infused into an Agilent
MSD (SL) electrospray mass spectrometer with ion trap detection.
HPLC analysis was performed on a Polaris C18 3×100 mm
3 µm column. Mobile phase: (A) 50 mM triethylammonium acetate
buffer (pH 5.8–6.2), 4% acetonitrile and (B) 50 mM triethylammo-
nium acetate buffer (pH 5.8–6.2), 80% acetonitrile. Gradient was
0–100% B over 10 min at 0.5 mL/min.
1H NMR was performed via a Bruker AVANCE, 600 MHz, in
D2O, TSP-d4. The numbering of the IRDye 800CW protons is
shown in Fig. 1a.
Under guidance from the US Food and Drug Administration, it
was not necessary to use dye manufactured under GMP for this
study; however, it was manufactured by LI-COR under a standard
operating protocol as specified by ISO9000-2000 system. ICG, lot
no. 81286 (USP lot no. 10B045), was obtained from Akorn, Inc.
(Lake Forest, IL). The chemical structures are shown in Fig. 1. The
test and control articles were diluted in sterile saline (Baxter
Healthcare, Deerfield, IL) and the homogeneity and concentrations
of the dosing solutions determined prior to injection.
Safety Study
This study was conducted according to US FDA Good Laboratory
Practice regulations 21CFR Part 58 at the GLP facilities at Baylor
School of Medicine under the direction of Dr. Marshall. The study
a n i m a l sw e r ea s s i g n e dt og r o u p sa ss h o w ni nT a b l e1.T oc o n t r o lf o r
bias, animals were stratified by weight in treatment groups. Animals
were injected intravenously with either 1, 5, or 20 mg/kg of the test
article or intradermally in the dorsal surfaces of both feet with a total
dose of 20 mg/kg.Animalswereobservedtwicedailyforupto 14days.
A complete necropsy was performed on all animals euthanized during
the course of the safety study. Euthanasia was accomplished by
exsanguination under isoflurane anesthesia. Blood was collected from
safety study animals for clinical chemistry, hematology, and electrolyte
analyses. Tissues and organs were processed from all animals
euthanized during the safety study and evaluated microscopically after
staining with hematoxylin and eosin at HSRL, Inc.
Clinical Pathology
Blood samples were collected while the animals were anesthetized
prior to euthanization by exsanguination. Approximately 0.5 mL of
Fig. 1. Structures of IRDye 800CW (a) and indocyanine
green (b).
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whenever possible. Hematology samples were placed in pediatric
collection tubes with K2 EDTA (BD Microtainer tubes #365974).
Blood samples obtained for serum chemistry were placed in 15-mL
conical polypropylene centrifuge tubes. After the samples had clotted,
the tubes were centrifuged at 2,500×g for 10 min, and the serum was
removed and transferred to a 1.5-mL polypropylene microcentrifuge
tube. Normal values for hematology, clinical chemistry, and electro-
lytes were obtained from several sources [12, 13]
Tissue Distribution
The animal groups for tissue distribution studies are shown inTable 1.
IRDye 800CW carboxylate (5 mg/kg) was administered IV via tail
vein or ID via the dorsal surface of the feet. Animals of both sexes
were exsanguinated while anesthetized 1 h after IV administration and
2 h after ID administration. Organs/tissues collected included brain,
liver, kidney, lung, spleen, muscle, reproductive organs, and popliteal
lymph nodes. Tissues were weighed, an equal volume of PBS added
per gram of tissue, and the tissues homogenized. When possible,
0.5mLofthehomogenatewasremovedandextractedwith0.75mLof
acetonitrile/methanol (AN/MeOH), 47:3 [14], for each 0.5 mL of
homogenate,vortexed for 30 s,andcentrifuged for10 min at 8,000×g.
Supernatants were removed, filtered with a 0.45-μm filter (Gelman
GHP Acrodisc 13), and placed in autosampler vials. Levels of
IRDye 800CW carboxylate present were determined by HPLC
(Agilent series 1100 liquid chromatograph) with diode array
detection. Because the popliteal lymph nodes and ovaries were
too small to homogenize, they were minced with a scalpel prior
to extraction with acetonitrile/MeOH.
Pharmacokinetics of IRDye 800CW
For pharmacokinetic analysis, animals were assigned to the groups
shown in Table 1. Approximately 0.2 mL of blood was collected
for analyses of test and control articles with K2 EDTA as an
anticoagulant. Time points utilized for ICG and IRDye 800CW
after IV administration included 0, 0.5, 1, 2, 5, 10, 15, 30, 45, and
60 min. Sampling times for ID injection were 0, 5, 10, 30, 60, 90,
120, 180, 240, 360, and 480 min. Blood was collected in pediatric
collection tubes with K2EDTA (BD Microtainer tubes #365974).
After centrifugation for 10 min at 2,500×g, plasma was removed and
extracted with AN/MeOH, 47:3 at a ratio of 1.5 mL AN/MeOH for
each milliliter of plasma. After vortexing the samples for 30 s, the
samples were centrifuged at 8,000×g for 10 min. The supernatant was
removed and filtered through a 0.45-μm filter and placed in
autosamplervialsforHPLCanalysis.Chromatographywasperformed
as indicated below. Analysis of sample results (peak areas) was
performed with SigmaPlot 10.0 for regression analysis. WinNonlin
Professional5.2wasusedtodeterminepharmacokineticparametersby
non-compartmental analysis and bolus administration (model 201 for
IV administration, model 200 for ID administration).
Chromatography
Dosing solutions, tissue extracts, and plasma extracts were analyzed
on an Agilent Model 1100 HPLC at 1 mL/min with a GL Sciences
InertsilODS-3 column(0.46×25 cm) with3-μm packing material and
a model 1100 diode array detector. The mobile phase consisted of
0.05 M triethylammonium acetate, pH 5.5–5.7, filtered through a
0.2-μm Gelman FP-Vericel filter, and acetonitrile. Gradient elution
was performed at ambient temperature using predetermined solvent
programs. External standards were used to determine plasma and
tissue concentrations as well as dosing solution concentrations.
Quantification of IRDye 800CW carboxylate and ICG was performed
by peak area analysis at 780 nm.
Statistical Analyses
Statistical analyses were performed with SigmaPlot 10.0 (Systat
Software, Inc., San Jose, CA) for regression analyses and SPSS
13.0 (SPSS, Inc. Chicago, IL). Typically, linear regression was
used to determine the detector response for analytical standards.
Means, standard deviations, standard errors, and analysis of
Table 1. Animal study groups
Groups Males
a Females
a Vehicle ICG (mg/kg) IRDye 800CW (mg/kg) Route of administration
b
Animal groups for safety study
1 12 12 Saline 0 0 IV
21 21 2 2 0 0 I V
31 21 2 0 1 I V
41 21 2 0 5 I V
5 14 16 0 20 IV
6 14 16 0 20 ID
Animal groups for tissue distribution study
16 6 5 I V
26 6 5 I D
Animal groups for pharmacokinetic study
1 2 Saline 0 0 IV
26 5 0 I V
36 0 5 I V
47
c 05 I D
aSix animals/sex/group were killed on day 2. The remaining animals were killed on day 15. Dosing was on day 1. Additional animals (2/sex/males, 4/sex/
females) were dosed at the highest level in case of toxicity. These animals were not evaluated histopathologically
bVolume of injections did not exceed 5 mL/kg
cOne animal was used to estimate optimal sampling times for IRDye 800CW given ID
M. V. Marshall et al.: Toxicity Study of IRDye 800CW in Rats 585variance were calculated with SPSS 13.0. Pharmacokinetic analyses
were performed with WinNonlin Professional 5.2 (Pharsight Corp.
Cary, NC).
Results
Characterization of IRDye 800CW
UV/vis and Fluorescence (1× PBS) measurements yielded
an absorption max. of 774 nm, an emission max. of 789 nm,
and an extinction coefficient 240,000. Purity by HPLC at
780 nm was 998%.
Mass spectrometry results were as follows: m/z [M+H
+]
calc. 1003.2, found 1,003.3, 100%; [M+2H
+] calc. 520.1,
found 502.1, 45%; [M+Na
+], calc. 1,025.3, found 1,025.2,
16%. The MS results are fully consistent with the expected
structure of the IRDye 800CW carboxylate dye.
1H NMR results were as follows: (labels refer to Fig. 1a)
A/A′ δ 7.71/7.74 (d, J=1.5 Hz, 2H); C/C′ δ 7.74/7.76 (dd,
J=1.5, 8.1/8.4 Hz, 2H); D/D′ δ 7.21/7.26 (d, J=8.3/8.4 Hz,
2H); K/K′ δ 7.77/7.82 (d, J=14/7/14.5 Hz, 2H); J/J′ δ 6.07/
6.13 (d, J=14.3/14.0 Hz, 2H); Q δ 7.25 (d, J=8.8 Hz, 2H);
R δ 7.85 (d, J=8.8 Hz, 2H); T/Z δ 3.97/3.97 (t, J=6.9 Hz,
4H); CC δ 2.97 (t, J=7.2Hz,2H);M/M′ δ 2.65(m, J=5.7 Hz,
4H); X δ 2.17 (t, J=7.5Hz,2H);Nδ 1.96 (m, J=5.6 Hz, 2H);
AA/BBδ1.85/1.82(m/m,4H);Uδ1.73(tt,J=7.5Hz,2H);W
δ 1.59 (tt, J=7.5 Hz,2H);V δ 1.36 (tt, J=7.7 Hz, 2H); I/I′ δ
1.26/1.25 (s, 12H).
The
1H NMR assignments were developed from the 1D,
COSY, HSQC, and HMBC spectra using standard pulse
sequences for those experiments.
Dosing Solution Analysis
Dosing solutions were analyzed to verify the amount of
material delivered to animals (Table 2). ICG was difficult to
dissolve in the saline vehicle. The instructions for the
preparation of ICG indicated that the lyophilized product
should be dissolved in sterile water, which was supplied by
the manufacturer. To facilitate solubility, samples were
placed in an ultrasonicator and repeatedly forced through a
syringe needle to aid solubility prior to administration. The
amount of ICG administered varied from 116.9% to 132.4% of
the intended dose at 20 mg/kg in the safety study. Animals in
thepharmacokineticstudyreceived95.5%oftheintendeddose
of 5 mg/kg. Homogeneity of the dosing solutions had a
coefficient of variation of 2.3–13.4% for the 20 mg/kg
solutions and 5.1% for the 5 mg/kg dosing solution.
In contrast, solubility of IRDye 800CW in saline was
good even at the 20-mg/kg dose level. The amount and
variation in the amount of ICG or IRDye 800CW at the
different dose levels is shown in Table 2.
Extraction Efficiency
The method for recovery of dye in plasma and tissue was
validated using spiked samples. Saline or plasma was spiked
with 50.0 μg/mL of ICG. For IRDye 800CW, plasma was
spiked with either 0.5 or 50.0 μg/mL of dye. The percent
recovery of ICG from saline was 103.9%, while recovery
from plasma was 78.1% based on triplicate analyses. After
samples were frozen for 1 day, recovery of ICG was 98.9%
for saline and 80.4% from plasma. With IRDye 800CW,
plasma recovery was 62.7% and 90.9% at 0.5 and 50 μg/mL,
respectively. When samples were frozen for 2 days, recovery
was 60.8% at 0.5 μg/mL and 82.0% at 50 μg/mL.
To test recovery from tissue, liver was spiked with IRDye
800CW (100 μg/1.0–1.5 g), homogenized, and extracted.
Recovery from liver was 56.9%. Analyses were done in
triplicate.
Clinical Observations
Animals were assigned to treatment groups according to
weight in order to avoid differences between groups. No
statistical significance between initial or final body weights
was observed between treatment groups, indicating that no
overt toxicity occurred. No toxic effects were observed
among any of the animals in this study during routine daily
observations. For some animals that received either indoc-
yanine green or IRDye 800CW following intravenous
injection, a green color persisted around the injection sites
for several days. For animals that received intradermal
injections of IRDye 800CW on the dorsal surface of the
feet, a green color persisted for several days on all animals.
No test or control article-related toxicity was observed at the
administration sites following histopathologic evaluation,
which correlated with clinical observations.
Tissue Distribution
Tissue distribution was determined in male and female rats
given 5 mg/kg of IRDye 800CW. Tissues and plasma were
obtained 1 h after IV administration of IRDye 800CW or 2 h
after ID administration and processed as described in
“Materials and Methods”. Overall means were similar for
males and females and between routes of administration for
lung, liver, spleen, and muscle (Fig. 2a, b). Slightly higher
levels of IRDye 800CW were seen in lung, spleen, and
muscle of males compared to females. Liver values were
lower after ID administration compared to IV administration.
The highest tissue levels were seen in kidney after IV
Table 2. Analysis of IRDye 800CW and ICG dosing solutions
Dose (mg/kg) IRDye 800CW ICG
% of Standard CV (%) % of Standard CV (%)
20 78.0–105.6 0.5–4.7 116.9–132.4 2.3–13.4
57 9 –104.8 0.6–10.2 95.5 5.1
1 81.1–95.9 0.5–2.2 ND ND
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to females. The reverse was true for ID administration.
Levels of IRDye 800CW were greater in ovaries than in
testes, and the amount of IRDye 800CW in ovaries was
greater in females after ID administration compared to IV
administration. No IRDye 800CW was detected in testes 2 h
after ID administration. IRDye 800CW was not detected in
brain following either IV or ID administration.
Uptake of IRDye 800CW in the popliteal lymph nodes
variedconsiderablywiththerouteofadministration(Fig.2c,d).
IRDye800CWlevelsweremuchgreaterafterIDadministration
compared to the IV route. Of all tissues, popliteal uptake was
greatest when normalized per gram of tissue after ID admin-
istration compared to other organs or tissues.
Pharmacokinetics
In addition to tissue distribution, the pharmacokinetics of
plasma levels of both ICG and IRDye 800CW were
performed. Pharmacokinetic analysis of IV ICG was
performed to serve as a control as published pharmacoki-
netic values were available for comparison. A single dose
level of 5 mg/kg was used for both IV and ID admin-
istration. ICG was only administered IV, whereas IRDye
800CW was administered both by the intravenous and
intradermal routes. Multiple injections were made in both
rear feet for all ID injections in this study.
Pharmacokinetic parameters were determined for IRDye
800CW and ICG using non-compartmental pharmacoki-
netics. Results of the clearance for IRDye 800CW following
IV and ID administration of 5 mg/kg are shown in Fig. 3a, c.
The time to peak plasma concentrations was fairly consistent
among animals after IV administration, but differed consid-
erably after ID administration. Average values were deter-
mined by combining the values obtained for individual
animals. The different times to reach peak plasma concen-
trations after ID administration may be a result of differences
in the release of IRDye 800CW. The terminal half-life of
ICG determined in this study (Fig. 3b), 6.2 min after IV
administration of 5 mg/kg, is similar to that reported in the
literature for humans and other species [15, 16]. Clearance
half-life of IRDye 800CW following IV injection was
determined to be 35.7 min, whereas the half-life following
ID injection was 236.5 min. Although urine levels of IRDye
800CW were not evaluated, green-colored urine was
observed in the bladders of animals in the tissue distribution
and pharmacokinetic studies, which indicates this was a
potential route of excretion. Excretion by the kidneys is also
indicated by the high tissue levels of IRDye 800CW in
kidneys of animals in the tissue distribution study.
Fig. 2. Uptake of dye by various organs. a Organ uptake 1 h after IV administration. b Organ uptake 2 h after ID administration.
The organ data are average values of six animals. c Popliteal uptake 1 h after IV administration. d Popliteal uptake 2 h after ID
administration. Data for popliteal uptake represent individual animals. The upper solid line represents the mean value of IRDye
800CW in males, and the lower solid line represents the mean value in females in both panels.
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Blood samples were collected from all animals in the safety
study just prior to euthanasia. When samples were clotted or
processing was delayed, unreliable values were obtained that
were not used to determine group responses. Group averages
for hematology data are summarized in Table 3, while data
for individual animals are shown in Electronic Supplemen-
tary Material (ESM) Fig. 1a–p. After statistical analyses
were performed on the data, no clinically significant dose-
related changes in hematology were observed 24 h or
14 days after exposure to the test or control articles for
either males or females.
For males, all parameters analyzed were generally within
the normal ranges for the respective tests (Table 3; ESM
Fig. 1a–p). A slight elevation was noted in the hematocrit
and hemoglobin of control males and high-dose IV IRDye
800CW groups, but were deemed insignificant. While slight
differences were noted between some of the values for day
15 as compared to day2, the values fell within the normal
ranges. There was no evidence of a dose or route of
administration-related response.
Values were similar for males and females with the
exception of white blood cells, which were slightly lower in
females. There was no evidence of a dose-related difference
between intravenous or intradermal administration.
Liver and Kidney Function
For males analyzed 24 h post-injection, all parameters were
within the normal range for the respective tests (Table 4;
ESM Fig. 2a–m), with the exception of LDH and creatine
kinase that were elevated outside the normal range in
animals that received the vehicle control of intravenous
saline. Alkaline phosphatase was elevated above the normal
range in all animals regardless of treatment.
At 15 days post-injection, all parameters analyzed for
male liver function were within the normal ranges for the
respective tests (Table 4; ESM Fig. 2a–m), with the
exception of GGT in the mid-dose IRDye 800CW group
and creatinine kinase in the high-dose IV IRDye 800CW
group that were elevated outside the normal range. Exami-
nation of the data for individual animals (ESM Fig. 2c, f)
indicated that the averages for these values were skewed by
a single animal. The average value for LDH (Table 4; ESM
Fig 2d) was similarly skewed in the ID IRDye 800CW
group by two animals. All of the individual skewed values
were from different animals. None of these animals had
more than a single value outside of the normal range.
Globulin was also elevated in the mid-dose IRDye 800CW
group, and total bilirubin was elevated in the ICG group. As
with the 24-h groups, alkaline phosphatase levels were
elevated above the normal range in all animals regardless of
treatment, except for the animals in the ID IRDye 800CW
group which was in the normal range. There was no
evidence of a dose-related response or from the two different
routes of administration. Overall, hepatic function test results
were similar in the 14-day and 24-h treatment animals. The
elevated values described above did not have any clinical
significance for the treatment groups 15 days after exposure
to the test or control article.
Similarly, females showed no evidence of a dose-related
response or differences from the two different routes of
administration 24 h post-injection (Table 4; ESM Fig. 2a–m).
Values obtained from females were similar to those seen in
males, with the exception of ALT and alkaline phosphatase
which were lower in females than in males. As seen in males,
Fig. 3. Clearance of IRDye 800CW and ICG from plasma. a
Clearance of IRDye 800CW following IV administration. b
Clearance of ICG following IV administration. c Clearance of
IRDye 800CW following ID administration.
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590 M. V. Marshall et al.: Toxicity Study of IRDye 800CW in RatsLDH and creatinine kinase were elevated outside the normal
range in animals that received the saline vehicle control
intravenously. LDH was also elevated above the high normal
range in animals that received ICG. ALT values were below
normal in animals that received the 5- and 20-mg/kg doses of
IRDye 800CW, but no clinical significance could be attributed
to this observation.
Again, at 15 days post-injection, there was no evidence of
a dose-related response or differences from the two different
routes of administration for liver function in females. Values
obtained from females were similar to those seen in males,
with the exception of alkaline phosphatase which was not
elevated in females compared to males. As seen in males,
LDH was slightly elevated outside the normal range in
females that received the saline vehicle control intrave-
nously. LDH was also slightly elevated after 14 days in the
vehicle control, ICG, and low-dose IRDye 800CW groups.
Creatine kinase was elevated in the vehicle control group.
Globulin levels were also elevated above the high normal
range in animals that received mid and high doses of IRDye
800CW. ALT values were below normal in animals that
received the 5- and 20-mg/kg doses of IRDye 800CW, but
no clinical significance could be attributed to this observa-
tion. Results from females 14 days after treatment were
similar to those from females in the 24-h treatment group.
Electrolytes
At 24 h post-injection, all parameters analyzed were within
the normal ranges for the respective tests for males and
females (Table 5). There was no evidence of either a dose or
route of administration-related response. Although potas-
sium and phosphorous levels were lower in females than
males, the difference was not clinically significant.
Fifteen days post-injection, all parameters analyzed were
within the normal ranges for the respective tests (Table 5)
for males and females, with the exception of the male mid-
dose IRDye 800CW group potassium levels in which the
mean was slightly lower than the low normal value. There
was no evidence of either a dose or route of administration-
related response.
Necropsy
Gross necropsies were conducted on all animals in the safety
study, including extra animals in the high-dose groups.
Because no lesions were observed in the extra animals, no
tissues were submitted for histopathologic evaluation. Some
animals in the highest group appeared to have excess red fluid
(presumably blood) around the brain, so additional rats were
included in the day 2 female high-dose groups, which were
dosed separately from the day 2 males. No consistent findings
were observed to verify the observations in males, and there
was no confirmation of adverse findings after histopathologic
evaluation of the brains of males or females in the day 2 or day
15groups,norwasthisseeninanimalsinthetissuedistribution
study that had 1- or 2-h exposures to the test article.
Organ Weights
Organs were weighed at necropsy to determine any gross
effects of the test or control article on specific organ
systems. No statistically significant differences were
observed between groups when absolute organ weights were
compared or when relative organ weights were compared.
One male rat in the day 15 ID IRDye 800CW group had an
enlarged spleen. On histopathologic evaluation of the spleen
from this animal, increased hemopoiesis (grade 1) was
noted. As grade 1 hemopoiesis was also seen in animals in
the vehicle control group and animals in other groups that
received test article by IV administration, the observation of
an enlarged spleen in this animal was deemed to be
unrelated to test article administration.
Discussion
This study was aimed at examining the toxicity of the NIR
dye IRDye 800CW for use in conjugates administered for
NIR fluorescence molecular imaging in humans. To our
knowledge, this is the first study of the toxicity of a NIR dye
with the potential for functionalization and labeling of
biomolecules. Fluorescein (excitation 494 nm, emission
518 nm) has been cleared by the United States Food and
Drug Administration as a contrast agent for angiography and
has been extensively used for the detection of choroidal
neovascularization associated with macular degeneration and
for intraoperative coronary angiography [17–21]. However,
fluorescein’s excitation and emission wavelengths are in a
region where significant tissue autofluorescence exists,
limiting its usefulness.
TheNIRdyeICGwasapprovedbytheFDAin1958[22]as
a contrast agent for retinal angiography. Since then, it has been
used extensively for angiographic analysis of a variety of
ocular pathologies [22]. In animals, a number of deleterious
effects have been reported following retinal injection and
prolonged exposure of the retinal pigment epithelium to ICG,
including cellular atrophy and the induction of apoptosis [23–
27]. In these studies, however, the dose of ICG was
significantly above the clinical dose in humans [23–27].
At the recommended ICG clinical dose (approximately
3.5 μg/kg) [25], human studies have reported adverse
reactions that include pain at the injection site, low blood
pressure, and itching [28, 29]. Fatal anaphylactic reactions
have been reported in two cases [28, 29]. However, the
estimated death rate due to administration of ICG is
extremely low [28, 29].
As noted above, the form of ICG approved for clinical
applications does not contain a reactive functional group
precluding its use as a general-purpose label for targeted
NIR contrast agents. Prior to human administration, an NIR
contrast agent must undergo a three-phase test in animals
M. V. Marshall et al.: Toxicity Study of IRDye 800CW in Rats 591T
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592 M. V. Marshall et al.: Toxicity Study of IRDye 800CW in Ratsconsisting of an examination of the toxicity of the dye, the
targeting moiety, and the final conjugate owing to the fact
that linking the targeting ligand and fluorophore results in a
new biomolecule that may have different properties.
In this study, we have examined the toxicity of IRDye
800CW at elevated levels with the intent of using it as a
signaling molecule for conjugation to ligands targeting a
variety of cellular biomolecules. Following histopathologic
evaluation of tissues, no systemic or local toxicity was
observed either 1 day or 14 days after either IV or ID
injection of either ICG or IRDye 800CW at doses up to
20 mg/kg. Minimal perivascular hemorrhage at the injection
site was seen in a few animals that received tail vein
injections. This change was sometimes accompanied by low-
grade inflammation and was considered to be the result of
venipuncture trauma. Based on hematologic and clinical
chemistry evaluations as well as the histopathologic exami-
nation, a single administration of IRDye 800CW IV at levels
of 1, 5, and 20 mg/kg or 20 mg/kg ID followed by 14 days
of observation produced no evidence of pathological effect
or toxicity. The 20-mg/kg dose was identified as the no
observed adverse effect level (NOAEL) for IRDye 800CW
administered either IV or ID. The NOAEL for ICG was also
20 mg/kg in this study. This is equivalent to a dose of 1.36 g
of dye injected per 68 kg individual, which is approximately
10,000 times more than the projected dose at which IRDye
800CW would be used.
Instrumentation capable of visualizing targeted agents
labeled with IRDye 800CW are in existence, and several
have regulatory clearance. The Zeiss Pentero (Carl Zeiss
GmbH) and the Leica FL800 (Leica Microsystems, USA)
have been used with ICG for surgical resectioning of
aneurysms and are predicted to be adaptable to intraoperative
surgical resection of tumors using NIR-labeled targeted agents.
The fluorescence-assisted resection and exploration instrumen-
tation system described by Tanaka [10], the optical system
described by Sevick-Muraca and coworkers [8, 9], and the
Artemis (O2View, Marken, the Netherlands) also have great
potential for NIR fluorescence molecular imaging.
A recent study [30] described the use of a novel
functionalized ICG to label Cetuximab in order to define
surgical margins; however, the authors concluded that ICG
lacked the sensitivity needed for use in a clinical setting. Given
that IRDye 800CW is 950 times brighter than ICG [9], it may
be especially suited for molecular imaging of disease markers
at picomolar to femtomolar tissue concentrations.
In parallel with this study, we are finalizing the filing of a
drug master file (DMF) with the US Food and Drug
Administration. The data from the completed toxicity study
combined with the DMF will enable us to participate in the
filing of several planned investigational new drug applications
for new contrast imaging agents for intraoperative surgery and
lymphatic analysis. IRDye 800CW dye made under GMP
compliancewillbeavailableforthesestudiesbythefirstpartof
2010. While more work remains to establish the safety and
efficacy of IRDye 800CW-labeled conjugates, the lack of
pathological effects of IRDye 800CW reported here is
promising. With the current environment of NIR fluorescence
instrument development,IRDye 800CW shouldimpactmolec-
ularimagingbyprovidingafunctionalizedNIRdye,enablinga
variety of new targeting contrast agents.
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